Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis.
Mathieu RoumiguiéXavier PaolettiYann NeuzilletRomain MathieuSébastien VincendeauFrançois KleinclaussArnaud MejeanLaurent GuyMarc Olivier TimsitThierry LebretPublished in: Future oncology (London, England) (2021)
Aim: Comparison of the efficacy/safety/health-related quality of life of apalutamide, enzalutamide and darolutamide in Phase III clinical trials involving patients with nonmetastatic castration-resistant prostate cancer was performed. Materials & methods: Relevant studies were identified by searching PubMed as well as conference abstracts reporting updated overall survival. Three pivotal trials were identified, SPARTAN (apalutamide), PROSPER (enzalutamide) and ARAMIS (darolutamide), and form the basis of this analysis. Results: All three drugs significantly prolonged metastasis-free survival, prostate-specific antigen response and overall survival versus placebo, and were generally well tolerated. Conclusion: Drug selection will likely be influenced by tolerability/safety and other factors, such as the propensity for drug-drug interactions and the presence of comorbidities, that affect the risk-benefit balance in individual patients.
Keyphrases
- free survival
- phase iii
- prostate cancer
- clinical trial
- open label
- double blind
- end stage renal disease
- phase ii
- placebo controlled
- adverse drug
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- drug induced
- randomized controlled trial
- emergency department
- patient reported outcomes
- patient reported